| |
 |
I remember talking to Tony [Dr. Anthony Fauci]. I said, “Well, let's
go talk to Ken Sell.” Ken was here at NIH. He was good; he made
a great contribution that I don't know will ever get recognized, because
it wasn't a publication or anything like that. But he saw the importance
of AIDS. He put the resources into it. We went down to his office and
explained to him why we wanted to use this [interleukin 2]. He said, “Two-hundred-and-fifty-thousand dollars–well, sounds like it should
be done. We'll do it.” I don't know if you went over to Dick [Dr.
Richard] Krause and Chuck [Charles] Leasure, who was the executive officer
at that time. I don't know where the money came from; it wasn't from a
Congressional appropriation. Somewhere there was the money and we were
able to get it. It wasn't a problem. Do you know Ken? Have you talked
to him?
Interviewer: Yes.
Lane: So he got the lab going over there; he brought the people over
to culture LAV [lymphadenopathy-associated virus]; he put the resources
in to get the thing. He really played a major role in getting the Institute
galvanized. It was my perception that he was instrumental in getting this
MACS [Multicenter AIDS Cohort Studies] work going. He said that we needed
to look at these people. This was before HIV. This is not my approach
to science–“Hey, I don't know what it is, but let's get 6,000
gay men and collect every secretion from their body and freeze it, and
some day it will be useful.” But that's important to do. You need
someone at that high a level to get it done. He was very instrumental
and very supportive. I give him a lot of credit. It's a tough position.
Everybody wants something from the scientific director. He clearly made
this priority, and I was impressed by that.
|
|
 |